{"nctId":"NCT00322231","briefTitle":"A Study of an Investigational Zoster Vaccine, in Subjects With a History of Herpes Zoster (V211-014)","startDateStruct":{"date":"2006-05"},"conditions":["Herpes Zoster"],"count":101,"armGroups":[{"label":"ZOSTAVAX™ / Placebo","type":"EXPERIMENTAL","interventionNames":["Biological: zoster vaccine live (ZOSTAVAX™)","Biological: Comparator: Placebo"]},{"label":"Placebo / ZOSTAVAX™","type":"EXPERIMENTAL","interventionNames":["Biological: zoster vaccine live (ZOSTAVAX™)","Biological: Comparator: Placebo"]}],"interventions":[{"name":"zoster vaccine live (ZOSTAVAX™)","otherNames":["Zostavax"]},{"name":"Comparator: Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Adults ≥ 50 years of age with a history of herpes zoster ≥ 5 years prior to enrollment\n\nExclusion Criteria:\n\n* History of allergy to any vaccine component\n* Prior receipt of a varicella or zoster vaccine\n* Ability to defend against infection is suppressed by a medical condition or medication","healthyVolunteers":true,"sex":"ALL","minimumAge":"50 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination","description":"SAEs are AEs at any dose that: Results in death or persistent/significant disability/incapacity; or prolongs an existing inpatient hospitalization or Is life threatening; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose or Is an other important medical event","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"101","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination","description":"The GMT of the VZV-specific antibody responses as measured by gpELISA (glycoprotein enzyme-linked immunosorbent assay) at the prespecified day ranges at prevaccination and 4 weeks postvaccination","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"810.1","spread":null},{"groupId":"OG001","value":"391.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) in VZV Antibody Titers From Prevaccination to 4 Weeks Postvaccination","description":"GMFR of the VZV antibody response at the prespecified day ranges prevaccination and 4 weeks postvaccination","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":null},{"groupId":"OG001","value":"1.0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":98},"commonTop":["Injection Site Pain","Injection Site Erythema","Injection Site Swelling","Injection Site Pruritus"]}}}